Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-26 13:21:38 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Rupee opens higher, may appreciate further on weak US dollar, decline in crude oil prices
- 75 years of Independence- Sensex from 100 to 59000, gauge for an undervalued stock called India
- Rupee to likely hold narrow range on elevated risk appetite, U
- Rupee opens higher amid retreat in dollar; rising risk in markets; USDINR to trade sideways in this range
- Safeguarding maritime security- Indian Navy’s vigilance in the Arabian Sea
- Markets Wrap – Mon, 19 Dec ‘22- Stocks rise, rupee appreciates; Asia, Europe markets, Gold, Crude, Crypto updates
- Rupee may fall to 83
- Rupee rises 33 paise to 81
- Mcap of BSE-listed firms at all-time high of over Rs 280